HRP20201375T1 - ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE - Google Patents
ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE Download PDFInfo
- Publication number
- HRP20201375T1 HRP20201375T1 HRP20201375TT HRP20201375T HRP20201375T1 HR P20201375 T1 HRP20201375 T1 HR P20201375T1 HR P20201375T T HRP20201375T T HR P20201375TT HR P20201375 T HRP20201375 T HR P20201375T HR P20201375 T1 HRP20201375 T1 HR P20201375T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- bcma
- heavy chain
- amino acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 19
- 102000036639 antigens Human genes 0.000 title claims 19
- 108091007433 antigens Proteins 0.000 title claims 19
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 24
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 24
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 102000046935 human TNFRSF17 Human genes 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000282553 Macaca Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004931 histamine dihydrochloride Drugs 0.000 claims 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Rekombinirano antitijelo, ili njegov fragment za vezanje antigena, koje se imunospecifično veže za BCMA, pri čemu antitijelo ima težak lanac i laki lanac, spomenuti teški lanac se sastoji iz:
a. područja 1 za određivanje komplementarnosti teškog lanca (CDR1) koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 4, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 5, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 6;
b. CDR1 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 7, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 5, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 6;
c. CDR1 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 4, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 5, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 19;
d. CDR1 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 4, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 8, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 6;
e. CDR1 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 13, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 5, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 19; ili
f. CDR1 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 13, CDR2 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 8, i CDR3 teškog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 19,
pri čemu se spomenuto antitijelo dalje sastoji iz CDR1 lakog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 24, CDR2 lakog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 25, i CDR3 lakog lanca koji ima aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 26.
2. Antitijelo, ili njegov fragment za vezanje antigena, prema zahtjevu 1, pri čemu težak lanac antitijela pod (a) se sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 27; težak lanac antitijela pod (a) se sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 57; težak lanac antitijela pod (c) se sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 39; težak lanac antitijela pod (d) se sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 40; ili težak lanac antitijela pod (e) se sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 58.
3. Antitijelo ili fragment za vezanje antigena prema zahtjevu 2, pri čemu laki lanac antitijela e sastoji iz aminokiselinske sekvence koja je predstavljena u SEQ ID NO: 28.
4. Antitijelo ili fragment za vezanje antigena prema bilo kojem od zahtjeva 1 do 3 pri čemu:
i) antitijelo ili njegov fragment za vezanje antigena se veže za vanstaničnu domenu ljudskog BCMA;
ii) antitijelo ili fragment za vezanje antigena je humano antitijelo ili fragment za vezanje antigena;
iii) fragment za vezanje antigena je Fab fragment, Fab2 fragment, ili jednolančano antitijelo;
iv) antitijelo ili njegov fragment za vezanje antigena inhibira interakciju BCMA i APRIL, što pri čemu antitijelo ili fragment za vezanje antigena izlaže IC50 za interakciju BCMA i APRIL od oko 5.9 nM kao što je mjereno sa ELISA;
v) antitijelo ili njegov fragment za vezanje antigena je IgG;
vi) antitijelo ili njegov fragment za vezanje antigena je IgG4 izotipa, na primjer pri čemu IgG4 ima S228P zamjenu, L234A zamjenu i L235A zamjenu u njegovom Fc području
vii) antitijelo ili njegov fragment za vezanje antigena imunospecifično veže ljudski BCMA i unakrsno reagira sa BCMA makaki majmuna;
viii) antitijelo ili njegov fragment za vezanje antigena veže BCMA na površini stanica ljudskog mijeloma; i/ili
ix) antitijelo ili njegov fragment za vezanje antigena veže BCMA na površini stanica humanog multiplog mijeloma.
5. Rekombinirana stanica koja izražava antitijelo ili fragment za vezanje antigena prema bilo kojem od zahtjeva 1 do 4, opcionalno pri čemu je stanica hibridom ili je antitijelo rekombinirano proizvedeno.
6. Rekombinirano BCMA x CD3 bispecifično antitijelo ili njegov BCMA x CD3 bispecifičan fragment za vezanje koji se sastoji iz:
a) prvog teškog lanca (HC1);
b) drugog teškog lanca (HC2);
c) prvog lakog lanca (LC1); i
d) drugog lakog lanca (LC2),
pri čemu je HC1 povezan sa LC1 i HC2 je povezan sa LC2 i pri čemu HC1 sadrži SEQ ID NO: 59, SEQ ID NO: 60, i SEQ ID NO: 61 kao CDR1-3 teškog lanca redom, i LC1 sadrži SEQ ID NO: 62, SEQ ID NO: 63, i SEQ ID NO: 64 kao CDR1-3 lakog lanca redom, da bi se oblikovalo prvo mjesto za vezanje antigena koje imunospecifično veže CD3 i pri čemu HC2 sadrži SEQ ID NO: 4, SEQ ID NO: 5, i SEQ ID NO: 6 kao CDR1-3 teškog lanca redom, i LC2 sadrži SEQ ID NO: 24, SEQ ID NO: 25, i SEQ ID NO: 26 kao CDR1-3 lakog lanca redom, da bi se oblikovalo drugo mjesto za vezanje antigena koje imunospecifično veže BCMA.
7. Rekombinirano BCMA x CD3 bispecifično antitijelo ili njegov fragment prema zahtjevu 6 koji se sastoji iz HC1 koji sadrži SEQ ID NO: 55, LC1 koji sadrži SEQ ID NO: 56, HC2 koji sadrži SEQ ID NO: 65, i LC2 koji sadrži SEQ ID NO: 76, što pri čemu, antitijelo ili bispecifičan fragment za vezanje je IgG.
8. BCMA x CD3 bispecifično antitijelo ili bispecifičan fragment za vezanje prema zahtjevu 6 ili zahtjevu 7 pri čemu antitijelo ili bispecifičan fragment za vezanje:
i) je IgG4 izotipa;
ii) imunospecifično veže ljudski BCMA s afinitetom od najmanje 0.22 nM kao što je mjereno površinskom plazmonskom rezonancom
iii) veže BCMA na površini stanica ljudskog mijeloma;
iv) veže BCMA na površini stanica ljudskog multiplog mijeloma;
v) inducira aktivaciju ljudskih T-stanica in vitro sa EC50 manjom od oko 0.37 nM;
vi) inducira T-staničnu zavisnu citotoksičnost stanica koje izražavaju BCMA in vitro sa EC50 manjom od oko 0.45 nM;
vii) nije BCMA agonist; i/ili
viii) ne mijenja aktivaciju NF-κB u koncentracijama koje su ispod 10 nM.
9. Rekombinirana stanica koja izražava antitijelo ili bispecifičan fragment za vezanje prema bilo kojem od zahtjeva 6 do 8, što pri čemu je stanica hibridom.
10. BCMA x CD3 bispecifično antitijelo ili bispecifičan fragment za vezanje prema bilo kojem od zahtjeva 6 do 8 za upotrebu u postupku:
i) za liječenje subjekta koji ima rak, opcionalno dalje obuhvaća davanje drugog terapeutskog agensa, na primjer pri čemu drugi terapeutski agens je kemoterapeutski agens ili ciljana anti-kancerogena terapija, kao što gdje kemoterapeutski agens je citarabin, antraciklin, histamin dihidroklorid, ili interleukin 2;
ii) za inhibiciju rasta ili proliferacije stanica raka; ili
iii) preusmjeravanja T stanice ka stanici raka koja izražava BCMA.
11. BCMA x CD3 bispecifično antitijelo ili bispecifičan fragment za vezanje za upotrebu prema zahtjevu 10 pri čemu je rak hematološki rak, na primjer pri čemu hematološki rak je rak B stanica koje izražavaju BCMA, što pri čemu rak B stanica koje eksprimiraju BCMA je multipli mijelom.
12. Farmacetuski sastav koji se sastoji iz BCMA x CD3 bispecifičnog antitijela ili bispecifičnog fragmenta za vezanje prema bilo kojem od zahtjeva 6 do 8 i farmaceutski prihvatljivog nosača.
13. Postupak za dobijanje BCMA x CD3 bispecifičnog antitijela ili bispecifičnog fragmenta za vezanje prema bilo kojem od zahtjeva 6 do 8 kultivacijom stanice prema zahtjevu 9.
14. Izolirani sintetički polinukleotid koji kodira BCMA x CD3 bispecifično antitijelo ili bispecifičan fragment za vezanje prema bilo kojem od zahtjeva 6 do 8.
15. Komplet koji se sastoji iz BCMA x CD3 bispecifičnog antitijela ili bispecifičnog fragmenta za vezanje kao što je definirano u bilo kojem od zahtjeva 6 do 8 i/ili polinukleotid kako je definirano u zahtjevu 14 i pakiranje istog.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206246P | 2015-08-17 | 2015-08-17 | |
EP16754148.1A EP3337824B1 (en) | 2015-08-17 | 2016-08-16 | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
PCT/US2016/047146 WO2017031104A1 (en) | 2015-08-17 | 2016-08-16 | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201375T1 true HRP20201375T1 (hr) | 2020-11-27 |
Family
ID=56740579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201375TT HRP20201375T1 (hr) | 2015-08-17 | 2020-08-28 | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE |
Country Status (40)
Country | Link |
---|---|
US (1) | US10072088B2 (hr) |
EP (2) | EP3757131A1 (hr) |
JP (3) | JP2018525005A (hr) |
KR (1) | KR20180040671A (hr) |
CN (1) | CN108350076B (hr) |
AR (1) | AR105724A1 (hr) |
AU (1) | AU2016308567B2 (hr) |
BR (1) | BR112018003017A2 (hr) |
CA (1) | CA2995754A1 (hr) |
CL (1) | CL2018000431A1 (hr) |
CO (1) | CO2018001524A2 (hr) |
CY (1) | CY1123297T1 (hr) |
DK (1) | DK3337824T3 (hr) |
EA (1) | EA201890513A1 (hr) |
EC (1) | ECSP18019568A (hr) |
ES (1) | ES2814550T3 (hr) |
FI (1) | FIC20230012I1 (hr) |
FR (2) | FR23C1012I1 (hr) |
HR (1) | HRP20201375T1 (hr) |
HU (2) | HUE050556T2 (hr) |
IL (2) | IL298041A (hr) |
JO (1) | JO3799B1 (hr) |
LT (2) | LT3337824T (hr) |
MA (1) | MA53750A (hr) |
MX (2) | MX2018002043A (hr) |
MY (1) | MY191325A (hr) |
NI (1) | NI201800027A (hr) |
NL (1) | NL301219I2 (hr) |
PE (1) | PE20180795A1 (hr) |
PH (1) | PH12018500361A1 (hr) |
PL (1) | PL3337824T3 (hr) |
PT (1) | PT3337824T (hr) |
RS (1) | RS60755B1 (hr) |
SI (1) | SI3337824T1 (hr) |
SV (1) | SV2018005634A (hr) |
TW (3) | TWI811023B (hr) |
UA (1) | UA127515C2 (hr) |
UY (1) | UY36859A (hr) |
WO (1) | WO2017031104A1 (hr) |
ZA (1) | ZA201801789B (hr) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
IL260732B1 (en) | 2016-02-17 | 2024-04-01 | Seagen Inc | BCMA antibodies and their use for the treatment of cancer and immune disorders |
SG11201809793UA (en) * | 2016-05-09 | 2018-12-28 | Bristol Myers Squibb Co | Tl1a antibodies and uses thereof |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
DK4050034T3 (da) | 2016-09-14 | 2024-06-03 | Teneoone Inc | Cd3-bindende antistoffer |
IL300729A (en) | 2016-12-21 | 2023-04-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
BR112019026803A2 (pt) * | 2017-06-20 | 2020-06-30 | Teneoone, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
IL271194B1 (en) * | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
IL272304B1 (en) * | 2017-08-01 | 2024-06-01 | Medimmune Llc | Conjugation of antibody with monoclonal BCMA drug |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
JP7385556B2 (ja) * | 2017-09-01 | 2023-11-22 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Bcma抗原に特異的な免疫原性ペプチドおよびその使用 |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
PE20201183A1 (es) * | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
BR112020008323A2 (pt) | 2017-11-01 | 2020-11-03 | Juno Therapeutics Inc | anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b |
BR112020009336A2 (pt) | 2017-11-15 | 2020-10-27 | Novartis Ag | receptor quimérico de antígenos de alvejamento de bcma, receptor quimérico de antígenos de alvejamento de cd19 e terapias de combinação |
BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
US11993658B2 (en) * | 2018-03-26 | 2024-05-28 | Sutro Biopharma, Inc. | Anti-BCMA antibodies and treatment methods |
KR20200143436A (ko) * | 2018-04-13 | 2020-12-23 | 아피메트 게엠베하 | Nk 세포 결합 항체 융합 구조체 |
MX2020012270A (es) * | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. |
BR112020024351A2 (pt) * | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
KR20210020932A (ko) | 2018-06-13 | 2021-02-24 | 노파르티스 아게 | Bcma 키메라 항원 수용체 및 이의 용도 |
EP3813878A4 (en) * | 2018-06-14 | 2022-03-16 | 2seventy bio, Inc. | CAR ANTI-BCMA ANTIBODIES, CONJUGATES AND METHODS OF USE |
KR102597053B1 (ko) * | 2018-06-26 | 2023-11-02 | 에이비엘바이오 주식회사 | 항-bcma 항체 및 그 용도 |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
CN112423785A (zh) | 2018-07-19 | 2021-02-26 | 瑞泽恩制药公司 | 双特异性抗BCMAx抗CD3抗体及其用途 |
EP3830122A1 (en) * | 2018-07-31 | 2021-06-09 | Amgen Research (Munich) GmbH | Dosing regimen for bcma-cd3 bispecific antibodies |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
TW202030323A (zh) | 2018-08-31 | 2020-08-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
IL297931A (en) | 2018-09-25 | 2023-01-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
CA3118397A1 (en) * | 2018-11-01 | 2020-05-07 | Shandong Newtime Pharmaceutical Co., Ltd. | Bispecific antibody targeting cd3 and bcma, and uses thereof |
EP3897720A4 (en) * | 2018-12-19 | 2022-12-07 | City of Hope | BAFF-R BISPECIFIC T-CELL ENGAGER ANTIBODY |
CA3128034A1 (en) * | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
KR20210134339A (ko) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | 바이러스 전달을 위한 메조다공성 실리카 입자 조성물 |
BR112021016791A2 (pt) * | 2019-02-26 | 2021-11-16 | Sorrento Therapeutics Inc | Proteínas de ligação de antígenos que se ligam a bcma |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
SG11202112120WA (en) * | 2019-05-03 | 2021-11-29 | Celgene Corp | Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same |
TW202108628A (zh) | 2019-06-14 | 2021-03-01 | 美商泰尼歐生物公司 | 與c d 2 2 及c d 3 結合之多特異性重鏈抗體 |
CN110229232B (zh) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 双特异性抗体及其用途 |
KR20220068984A (ko) * | 2019-07-30 | 2022-05-26 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도 |
WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
MX2022006714A (es) * | 2019-12-06 | 2022-08-08 | Regeneron Pharma | Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos. |
JP2023506162A (ja) * | 2019-12-10 | 2023-02-15 | エービーエル バイオ インコーポレイテッド | 抗bcma/抗4-1bb二重特異性抗体及びその用途 |
WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
WO2021127007A1 (en) * | 2019-12-16 | 2021-06-24 | Bluebird Bio, Inc. | Anti-bcma car antibodies, conjugates, and methods of use |
EP4110377A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
BR112022017148A2 (pt) | 2020-02-27 | 2022-11-08 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
UY39127A (es) * | 2020-03-13 | 2021-09-30 | Janssen Biotech Inc | Materiales y métodos para modular la inmunidad mediada por cadena delta |
TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子,其製備方法及醫藥用途 |
TW202330622A (zh) * | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
US20230203161A1 (en) * | 2020-04-29 | 2023-06-29 | Teneobio, Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
AU2021272291A1 (en) | 2020-05-11 | 2023-02-02 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
KR20230013258A (ko) | 2020-05-19 | 2023-01-26 | 얀센 바이오테크 인코포레이티드 | T 세포 재유도 치료제 및 vla-4 부착 경로 억제제를 포함하는 조성물 |
AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
CA3189297A1 (en) | 2020-06-30 | 2022-01-06 | Nathan Trinklein | Multi-specific antibodies binding to bcma |
CN114075287B (zh) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
CA3188978A1 (en) | 2020-08-21 | 2022-02-24 | Sandeep Tharian Koshy | Compositions and methods for in vivo generation of car expressing cells |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
WO2022098771A1 (en) * | 2020-11-03 | 2022-05-12 | Ab Studio Inc. | Multispecific antibodies and uses thereof |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022135468A1 (zh) * | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 抗bcma×cd3双特异性抗体及其用途 |
KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
BR112023016121A2 (pt) | 2021-02-16 | 2023-11-28 | Janssen Pharmaceutica Nv | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 |
EP4301785A1 (en) * | 2021-03-05 | 2024-01-10 | Atreca, Inc. | Epha2 antibodies |
CA3214594A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
TW202309294A (zh) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物 |
CA3221399A1 (en) | 2021-05-28 | 2022-12-01 | Janssen Biotech, Inc. | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
CN115521381A (zh) * | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
CN115569191A (zh) * | 2021-07-05 | 2023-01-06 | 山东新时代药业有限公司 | 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂 |
WO2023020474A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies and uses thereof in cancer therapies |
EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
WO2023076921A1 (en) * | 2021-10-27 | 2023-05-04 | Janssen Biotech, Inc. | Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue |
AU2022380155A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
WO2023086817A1 (en) * | 2021-11-10 | 2023-05-19 | Janssen Biotech, Inc. | Stable formulations comprising a bispecific bcma/cd3 antibody |
WO2023098846A1 (zh) * | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
CN117003871A (zh) * | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024095173A1 (en) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
WO2024119126A1 (en) * | 2022-12-02 | 2024-06-06 | Artiva Biotherapeutics, Inc. | Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CN117186229B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1538206B1 (en) | 1997-09-16 | 2010-03-24 | Centocor, Inc. | Method for the complete chemical synthesis and assembly of genes and genomes |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Bcma及びtaciの両者を結合する抗体 |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス, インコーポレイテッド | B細胞上でのbcmaタンパク発現レベル及び診断法における使用 |
DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
RS55218B1 (sr) | 2008-10-31 | 2017-02-28 | Janssen Biotech Inc | Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe |
JP5873335B2 (ja) | 2009-02-12 | 2016-03-01 | ヤンセン バイオテツク,インコーポレーテツド | フィブロネクチンiii型ドメインに基づくスカフォールド組成物、方法及び使用 |
MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
MX353144B (es) | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
JP2014500879A (ja) * | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
CN107936121B (zh) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
AU2012289926A1 (en) * | 2011-08-03 | 2014-03-13 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
-
2016
- 2016-08-16 HU HUE16754148A patent/HUE050556T2/hu unknown
- 2016-08-16 CN CN201680060812.2A patent/CN108350076B/zh active Active
- 2016-08-16 AU AU2016308567A patent/AU2016308567B2/en active Active
- 2016-08-16 SI SI201630895T patent/SI3337824T1/sl unknown
- 2016-08-16 UA UAA201802674A patent/UA127515C2/uk unknown
- 2016-08-16 PL PL16754148T patent/PL3337824T3/pl unknown
- 2016-08-16 JP JP2018508695A patent/JP2018525005A/ja active Pending
- 2016-08-16 MX MX2018002043A patent/MX2018002043A/es unknown
- 2016-08-16 WO PCT/US2016/047146 patent/WO2017031104A1/en active Application Filing
- 2016-08-16 TW TW111126438A patent/TWI811023B/zh active
- 2016-08-16 LT LTEP16754148.1T patent/LT3337824T/lt unknown
- 2016-08-16 KR KR1020187007297A patent/KR20180040671A/ko not_active Application Discontinuation
- 2016-08-16 EP EP20177664.8A patent/EP3757131A1/en active Pending
- 2016-08-16 MY MYPI2018700579A patent/MY191325A/en unknown
- 2016-08-16 BR BR112018003017-1A patent/BR112018003017A2/pt active Search and Examination
- 2016-08-16 MA MA053750A patent/MA53750A/fr unknown
- 2016-08-16 PT PT167541481T patent/PT3337824T/pt unknown
- 2016-08-16 JO JOP/2016/0184A patent/JO3799B1/ar active
- 2016-08-16 PE PE2018000262A patent/PE20180795A1/es unknown
- 2016-08-16 TW TW112124028A patent/TW202406935A/zh unknown
- 2016-08-16 CA CA2995754A patent/CA2995754A1/en active Pending
- 2016-08-16 TW TW105126031A patent/TWI777924B/zh active
- 2016-08-16 US US15/237,889 patent/US10072088B2/en active Active
- 2016-08-16 DK DK16754148.1T patent/DK3337824T3/da active
- 2016-08-16 EP EP16754148.1A patent/EP3337824B1/en active Active
- 2016-08-16 ES ES16754148T patent/ES2814550T3/es active Active
- 2016-08-16 RS RS20201050A patent/RS60755B1/sr unknown
- 2016-08-16 EA EA201890513A patent/EA201890513A1/ru unknown
- 2016-08-16 IL IL298041A patent/IL298041A/en unknown
- 2016-08-17 UY UY0001036859A patent/UY36859A/es active IP Right Grant
- 2016-08-17 AR ARP160102519A patent/AR105724A1/es unknown
-
2018
- 2018-02-11 IL IL257468A patent/IL257468B2/en unknown
- 2018-02-15 PH PH12018500361A patent/PH12018500361A1/en unknown
- 2018-02-16 CL CL2018000431A patent/CL2018000431A1/es unknown
- 2018-02-16 NI NI201800027A patent/NI201800027A/es unknown
- 2018-02-16 CO CONC2018/0001524A patent/CO2018001524A2/es unknown
- 2018-02-16 MX MX2022006650A patent/MX2022006650A/es unknown
- 2018-02-16 SV SV2018005634A patent/SV2018005634A/es unknown
- 2018-03-14 EC ECIEPI201819568A patent/ECSP18019568A/es unknown
- 2018-03-16 ZA ZA201801789A patent/ZA201801789B/en unknown
-
2020
- 2020-08-28 CY CY20201100810T patent/CY1123297T1/el unknown
- 2020-08-28 HR HRP20201375TT patent/HRP20201375T1/hr unknown
-
2021
- 2021-07-30 JP JP2021126285A patent/JP7194240B2/ja active Active
-
2022
- 2022-12-08 JP JP2022196582A patent/JP2023027228A/ja active Pending
-
2023
- 2023-02-22 FR FR23C1012C patent/FR23C1012I1/fr active Active
- 2023-02-22 FI FIC20230012C patent/FIC20230012I1/fi unknown
- 2023-02-22 NL NL301219C patent/NL301219I2/nl unknown
- 2023-02-22 FR FR23C1011C patent/FR23C1011I1/fr active Active
- 2023-02-22 HU HUS2300011C patent/HUS2300011I1/hu unknown
- 2023-02-23 LT LTPA2023509C patent/LTPA2023509I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
JP2019524693A5 (hr) | ||
HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
IL272572A (en) | Antibiotics to treat cancer | |
HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
JP2018532383A5 (hr) | ||
HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
JP2020510422A5 (hr) | ||
RU2017105915A (ru) | Антитела против pd-1 | |
HRP20221323T1 (hr) | Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe | |
JP2012525829A5 (hr) | ||
PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
JP2018519364A5 (hr) | ||
HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
JP2017535257A5 (hr) | ||
JP2017530722A5 (hr) | ||
RU2017123549A (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
JP2017149720A5 (hr) | ||
JP2016505556A5 (hr) | ||
JP2013198490A5 (hr) | ||
JP2016533763A5 (ja) | ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 |